公告显示，思坦仪器2020年至2024年累计亏损3411.38万元，公司通过转让思坦仪器股权，取得股权转 让价款3.7亿元，上述资金回笼将进一步增加公司"发展第二增长曲线"的资金储备。 海默科技（300084）(300084.SZ)公告，公司拟出售控股子公司西安思坦仪器股份有限公司全部股权。 公司拟与西安精英光电技术有限公司("精英光电")、吴彦林先生签订《海默科技(集团)股份有限公司与 西安精英光电技术有限公司吴彦林关于西安思坦仪器股份有限公司之股份转让协议》，以3.7亿元的价 格将所持思坦仪器全部股权转让给精英光电。 本次交易的标的股份为公司持有的思坦仪器99.33%的股份，包含思坦仪器所持有的西安思坦软件技术 有限公司("思坦软件")100%股权和思坦仪器所持有的西安思坦油气工程服务有限公司("思坦油服")100% 股权。交易完成后，公司不再持有思坦仪器股份，思坦仪器不再纳入公司合并报表范围。 ...

Core Viewpoint - Hualan Co., Ltd. has signed an agreement to transfer its 30% stake in Jiaxing Yuanfan to Shanghai Hongyuan Investment Group for RMB 12 million, aligning with its strategic layout and future development plans [1] Group 1: Transaction Details - The company will sell its 30% property share in Jiaxing Yuanfan, which includes a subscribed capital of RMB 30 million and a paid-in capital of RMB 12 million, for RMB 12 million [1] - After the transfer, the company will no longer hold any property shares in Jiaxing Yuanfan [1] Group 2: Strategic Implications - The transaction is aimed at improving the company's financial situation by recovering funds and allowing the company to focus on its core business [1] - The move is expected to enhance asset operation efficiency and have a positive impact on the company's financial status [1] - The transaction was conducted under principles of openness, fairness, and justice, ensuring no harm to the interests of the company and its shareholders [1]

Core Insights - The company aims to continue divesting non-core, non-strategic, low-efficiency, and loss-making assets by 2025 to enhance cash flow [1][2][3] - In 2024, the company reported a revenue of 41.067 billion yuan, a year-on-year decrease of 0.8%, while net profit attributable to shareholders increased by 16.1% to 2.77 billion yuan [1] - The operating cash flow for 2024 was 4.48 billion yuan, reflecting a year-on-year growth of 31.1%, surpassing the growth rate of operating profit [1] Asset Management Strategy - The company has been actively selling assets to replenish working capital and repay interest-bearing debts, including the sale of a 6.01% stake in Gland Pharma for a total consideration of 211 million USD [2] - In March 2025, the company announced the sale of 9.4 million shares of Unicorn II Holdings Limited for 124 million USD, resulting in a complete exit from the company [2] - The company has recognized the need to streamline its asset portfolio, focusing on core business areas to improve asset efficiency and structure [3] Financial Health - As of the end of 2024, the company's debt-to-asset ratio was 48.98%, a slight decrease from 50.10% at the end of 2023, indicating ongoing debt pressure [3]